Reductions in A1C from baseline (%) across doses and trials1
Panel of 5 lollipop graphs showing the mean change in A1C at primary endpoint for adults with type 2 diabetes in the SURPASS 1-5 studies. The first graph shows Mounjaro vs placebo as monotherapy. From a mean baseline A1C of 8.0% (Mounjaro 5 mg, n=121), 7.9% (Mounjaro 10 mg, n=121), 7.9% (Mounjaro 15 mg, n=120), and 8.1% (placebo, n=113), mean change in A1C at 40 weeks was -1.8%, -1.7%, -1.7%, and -0.1%, respectively.
The second graph shows Mounjaro vs Ozempic 1 mg as add-on to metformin. From a mean baseline A1C of 8.3% in all treatment arms (Mounjaro 5 mg, n=470; Mounjaro 10 mg, n=469; Mounjaro 15 mg, n=469; and Ozempic 1 mg, n=468), mean change in A1C at 40 weeks was -2.0%, -2.2%, -2.3%, and -1.9%, respectively.
The third graph shows Mounjaro vs Tresiba as add-on to metformin with or without SGLT2i. From a mean baseline A1C of 8.2% in all Mounjaro treatment arms (Mounjaro 5 mg, n=358; Mounjaro 10 mg, n=360; Mounjaro 15 mg, n=358) and 8.1% for Tresiba (n=359), mean change in A1C at 52 weeks was -1.9%, -2.0%, -2.1%, and -1.3%, respectively.
The fourth graph shows Mounjaro vs insulin glargine as add-on to 1-3 oral antihyperglycemic medications (metformin, SGLT2i, or sulfonylurea). From a mean baseline A1C of 8.5% (Mounjaro 5 mg, n=328), 8.6% (Mounjaro 10 mg, n=326), 8.5% (Mounjaro 15 mg, n=337), and 8.5% (insulin glargine, n=998), mean change in A1C at 52 weeks was -2.1%, -2.3%, -2.4%, and -1.4%, respectively.
The fifth graph shows Mounjaro vs placebo as add-on to basal insulin with or without metformin. From a mean baseline A1C of 8.3% (Mounjaro 5 mg, n=116), 8.4% (Mounjaro 10 mg, n=118), 8.2% (Mounjaro 15 mg, n=118), and 8.4% (placebo, n=119), mean change in A1C at 40 weeks was -2.1%, -2.4%, -2.3%, and -0.9%, respectively.